Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Parsaclisib Is a Next-Generation PI3Kδ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy

(2020) Niu Shin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors

(2020) Ashley Hanlon et al.   Hematology-American Society of Hematology Education Program

Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia

(2019) Steven T. Bird et al.   JAMA Oncology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Idelalisib in the management of lymphoma

(2016) C. Y. Cheah et al.   BLOOD

Idelalisib—targeting PI3Kδ in patients with B-cell malignancies

(2014) Jan A. Burger et al.   Nature Reviews Clinical Oncology